Clinical benefit within patient subgroups receiving c7E3 Fab (abciximab) during percutaneous coronary revascularization: Subgroup analysis from the EPIC trial

Frank V. Aguirre, Eric J. Topol, Keaven M. Anderson, Neal S. Kleiman, Harlan F. Weisman, Susan E. FitzPatrick, Robert M. Califf

Research output: Contribution to journalArticlepeer-review

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)21B-29B
JournalJournal of Invasive Cardiology
Issue numberSUPPL. B
StatePublished - 1996
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Cite this